This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.03% per year. These returns cover a period from January 1, 1988 through July 1, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Buy Abbott (ABT) Stock Ahead of Earnings on Coronavirus Testing Push?
by Benjamin Rains
The FDA has approved two different Abbott coronavirus tests. So now the question for investors is should they consider buying ABT shares with the firm set to report its Q1 fiscal 2020 financial results on Thursday, April 16?
Solid Diagnostics to Aid Abbott (ABT) Q1 Earnings Amid Crisis?
by Zacks Equity Research
Though the magnitude of loss due to the virus outbreak in Abbott's (ABT) Core Laboratory business is still unclear, the company's point-of-care business is anticipated to generate profit.
Amazon (AMZN) to Boost Worker Safety With Testing Lab Facility
by Zacks Equity Research
Amazon (AMZN) to build coronavirus testing lab to ensure safety of its workers.
Will Low Product Revenues Impact Abbott (ABT) Q1 Earnings?
by Zacks Equity Research
Revenues of Abbott's (ABT) Diabetes Care business, which has been, otherwise on a strong growth trajectory, are likely to have declined in Q1 due to the coronavirus-related market turbulence.
Coronavirus Testing, Vaccines & Treatments: What You Should Know
by Neena Mishra
We discuss latest developments in tests, vaccines and therapies for COVID-19.
Earnings Preview: Abbott (ABT) Q1 Earnings Expected to Decline
by Zacks Equity Research
Abbott (ABT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Bull of the Day: Penumbra (PEN)
by Kevin Cook
This $5 billion innovator removes blood clots and the deadly shadow of stroke with catheter-based aspiration technologies
What to Expect from Big Bank Earnings Amid the Coronavirus?
by Sheraz Mian
The S&P 500 index is now down -14% this year through Thursday, April 9, while the Major Banks industry is still down more than -37%. This underperformance is not surprising, given the group's exposure to a sharp economic downturn...
Abbott (ABT) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
Abbott (ABT) closed the most recent trading day at $81.90, moving -1% from the previous trading session.
Luminex (LMNX) Receives EUA for Coronavirus Detection Test
by Zacks Equity Research
Luminex (LMNX) receives EUA for its ARIES SARS-CoV-2 Assay, which will be used to rapidly detect the virus causing COVID-19.
These Medical ETFs & Stocks Deserve a Salute on Health Day
by Sanghamitra Saha
The World Health Day of 2020 puts these medical companies and the related stocks and ETFs in focus.
Amazon (AMZN) in Talks With Test Makers to Screen Workers
by Zacks Equity Research
Amazon (AMZN) is in contact with Abbott Laboratories and Thermo Fisher Scientific to introduce coronavirus testing at its warehouses.
Healthcare Stocks & ETFs to Gain on Coronavirus Test Progress
by Sweta Jaiswal, FRM
It seems that testing for COVID-19 is the major key in controlling the outbreak and helps in making decisions like treatment protocols, resource allocation and drafting the right healthcare policies.
BD Gets EUA for New Test to Combat the Coronavirus Crisis
by Zacks Equity Research
BD (BDX) partners with BioGX to introduce a new diagnostic test to help hospitals boost the capacity of quick, on-site testing of COVID-19.
Healthcare ETFs Gain on Rising Demand for COVID-19 Tests
by Sweta Jaiswal, FRM
A growing demand for COVID-19 tests has indulged major healthcare place in the race to develop competent testing kits.
Abbott (ABT) in Focus: Stock Moves 6.4% Higher
by Zacks Equity Research
Abbott (ABT) saw a big move last session, as its shares jumped more than 6% on the day, amid huge volumes.
Abbott (ABT) Rides on Point-of-Care Coronavirus Test Launch
by Zacks Equity Research
Abbott (ABT) launches a portable molecular point-of-care test to speed up coronavirus detection, especially in areas with severe outbreaks.
Here's Why You Should Hold on to Abbott (ABT) Stock for Now
by Zacks Equity Research
Investors continue to be optimistic about Abbott (ABT) on its strong segmental results in the fourth quarter of 2019.
Stock Market News for Mar 31, 2020
by Zacks Equity Research
Benchmarks gained on Monday, boosted by healthcare companies that are trying their best to bring the pandemic to a halt.
4 MedTech Stocks Set to Rebound Post Coronavirus-Led Crisis
by Zacks Equity Research
Here are some MedTech stocks which are steadily inching toward a trend reversal after registering record declines over the past few weeks.
Luminex (LMNX) Receives EUA for Coronavirus Detection Test
by Zacks Equity Research
Luminex (LMNX) receives EUA for its NxTAG CoV Extended Panel that will be used to detect the SARS-CoV-2 virus.
4 Stocks Countering Coronavirus Battle With Testing Kits
by Urmimala Biswas
While the market bloodbath is showing no signs of dissipating any time soon, investors might keep an eye on certain genetic testing and medical device companies.
FDA EUA for Coronavirus Tests Boosts MedTech: 3 Stocks in Focus (Revised)
by Sriparna Ghosal
These key biotech and molecular diagnostic players banking on the receipt of FDA's EUA for COVID-19 tests are currently outperforming the broader industries they belong to.
FDA EUA for Coronavirus Tests Boosts MedTech: 3 Stocks in Focus
by Sriparna Ghosal
These key biotech and molecular diagnostic players banking on the receipt of FDA's EUA for COVID-19 tests are currently outperforming the broader industries they belong to.
Bull of the Day: Edwards Lifesciences (EW)
by Kevin Cook
While most elective procedures are being deferred, the innovator of minimally-invasive heart valve replacement beats on